Biological Modulation of the Treg:Teff Ratio: From Immunosuppression to Immunoactivation by Yang, Xining & Scott, Mark D.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books










Xining Yang and Mark D. Scott
Abstract
T cell-mediated immunomodulation can be, in simple terms, defined as altering
the normal Treg:Teff ratio. Immunosuppression skews the net Treg:Teff ratio
toward the ‘tolerogenic’ Treg component, while immunoactivation skews the
response toward the ‘proinflammatory’ Teff component. In the treatment of auto-
immune diseases, achieving an immunosuppressive state is a desirable goal in order
to prevent ongoing injury by activated Teff cells. In contrast, an innate, or induced,
immunosuppressive state can be deleterious and prevent pathogen-induced disease
while allow for the progression of cancer. Indeed, a current goal of cancer therapy is
attenuating an existing endogenous immunosuppressive state that prevents effec-
tive T cell-mediated immunorecognition of cancer cells. Thus, the biological modu-
lation of the Treg:Teff ratio provides a unique approach for treating both
autoimmune diseases and cancers. Using a biomanufacturing system, miRNA-
enriched immunotherapeutic has been generated that either induce (TA1) or over-
come (IA1) an immunosuppressive state. As will be shown, these therapeutics show
efficacy both in vitro and in vivo in the prevention of autoimmune Type 1 diabetes
and in enhancing the ability of resting immune cells to recognize and inhibit cancer
cell growth. The successful development of these cost-effective, and easily
biomanufactured, secretome-based therapeutics may prove useful in treating both
autoimmune diseases and cancer.
Keywords: T lymphocyte, immunosuppression, immunoactivation, Treg, Teff,
proinflammatory, autoimmunity, cancer, biomanufacturing, miRNA
1. Introduction
The core function of the immune system is preserving ‘self ’ and rejecting
‘non-self’. Biologically, ‘non-self’ is most often seen as exogenous biologicals (e.g.,
viruses and bacteria), abnormal autologous cells (e.g., cancers) and, more recently,
‘man-made diseases’ arising from the purposeful introduction of ‘non-self’ (e.g.,
enzyme-replacement therapy, transfusion and transplantation medicine). Immu-
nological ‘self ’ of most tissues is imparted by the major histocompatibility complex
(MHC) which encodes a variety of proteins that provide a means for identifying,
targeting, and eliminating foreign invaders and diseased cells while preserving
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normal ‘self ’ tissue [1–3]. The MHC proteins themselves consist of three classes.
MHC Class I molecules are expressed on virtually all nucleated cells while Class II
molecules are expressed exclusively on antigen presenting cells (APC; e.g., mono-
cytes, macrophages, dendritic cell, B lymphocytes, and endothelial cells) and acti-
vated T lymphocytes. MHC Class III genes encode components of the complement
system. The human MHC is referred to as the Human Leukocyte Antigen (HLA)
complex while the murine equivalent is referred to as the Histocompatibility-2 (H2)
complex. In the context of MHC-mediated immune recognition, the T lymphocyte
(T cell) is of particular importance and plays a (the) central role in transfusion-
associated graft versus host disease, transplant rejection, autoimmune diseases and
cancer therapy. In terms of human diseases, autoimmune disorders and cancer are
of most significance clinically.
The activation status of T cells plays a critical role in normal immunological
homeostasis, the response to cancers, rejection of tissue/organ grafts, and the
ontogeny and pathophysiology of autoimmune diseases. T cells encompass multi-
ple subpopulations that can exert either a protolerogenic effects (regulatory T
cells; Tregs) or a proinflammatory responses (effector T cells; Teff). Hence, in
examining the immune status, the relative abundance of Tregs and Teff, i.e., the
Treg:Teff ratio, is critical. Indeed, skewing the immune response towards either
end of the continuum leads to significant medical consequences. As shown in
Figure 1, an immunosuppressive state (increased Treg and/or decreased Teff)
may facilitate the growth and spread of abnormal (i.e., cancer) cells, or in the
context of transplantation medicine enhance engraftment, while a
proinflammatory state (decreased Tregs and/or increased Teff) that may give rise
to an autoimmune disease, graft rejection or, in the case of cancer, enhance tumor
cell elimination. Indeed, modern clinical approaches attempt to pharmacologically
modulate the Treg:Teff ratio in the treatment of autoimmune disease, tissue
transplantation and cancer therapy.
Figure 1.
The yin and yang of the cellular immune response. A key aspect of immune regulation is the dualism of the
tolerogenic (Treg; e.g., Foxp3+, IL-10+,TGF-β+ and IL-4+) and effector (Teff; e.g.,Th17+, IL-2+, INF-γ+ IL-12
+, and TNF-β+) CD4+ T cells. Effector T cells also include cytotoxic CD8+ T cells (CTL). These seemingly
disparate cellular subpopulations are actually complementary, interconnected, and interdependent in
regulating the immunological response. As such, the immune response is a continuum that may be best reflected
by the Treg:Teff ratio. Indeed, the skewing of the Treg:Teff ratio towards either the left or right influences the
immunological risks/benefits of an animal. As shown, a skewed response towards the Treg cells may prevent
T1D or could be used to prevent rejection of transplanted islets. In contrast, skewing towards the Teff
populations increases the risk of autoimmune diseases such as type 1 diabetes (T1D) consequent to the
development of insulitis of the islet cells.
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2. Autoimmune diseases: increasing the Treg:Teff ratio
Autoimmune diseases affect virtually all tissues and organs and encompass such
diverse diseases as Type 1 Diabetes (T1D), Crohn’s disease (CD), Multiple Sclerosis
(MS), Rheumatoid Arthritis (RA) and immune thrombocytopenia (ITP). Despite
the diversity of tissues affected, extensive research has demonstrated the central
role for T cells with Treg being downregulated and Teff upregulated leading to a
reduced Treg:Teff ratio and a chronic pro-inflammatory state (Figure 1). Current
clinical approaches to regulating the Treg:Teff ratio are almost entirely focused on
reducing the Teff component. Most commonly, treatments for chronic autoimmune
diseases include administration of systemic steroids (e.g., dexamethasone), cyto-
toxic anti-proliferative/activation agents (e.g., cyclosporine), and interruption of
proinflammatory cytokine signaling cascades (e.g., Enbrel) resulting in the induc-
tion of a general immunosuppressive state in the individual (Figure 2). While these
pharmacological approaches are often highly effective in controlling the autoim-
mune disease, they also pose significant risks to the individual including increased
risks of opportunistic infections, cancer and organ injury. Perhaps surprisingly,
very few clinical tools exist to increase the Treg component of the Treg:Teff ratio.
Importantly, an increase in the functional Treg component would be very effective
at reducing the damage induced by the Teff subsets in autoimmune diseases and
decreasing the risk of Host versus graft disease in tissue/organ transplantation.
3. Cancer immunotherapy: decreasing the Treg:Teff ratio
In contrast to autoimmune diseases, immunosuppressive states (i.e., increased
Treg:Teff ratio) exist resulting in a failure to appropriately respond to abnormal
Figure 2.
Current pharmacologic therapies almost exclusively targets T cell activation and the Teff subpopulations. The
proliferation of pro-inflammatory T cells (e.g., CTL,Th17,Th1 populations) and decrease in regulatory T cells
(Treg) are commonly observed in both autoimmune and allorecognition immune responses. The majority of
current therapeutic agents are primarily cytotoxic agents preventing T cell activation (e.g., cyclosporine and
rapamycin) or T cell proliferation (e.g., methotrexate, corticosteroids and azathioprine). Additionally, some
blocking antibodies have been investigated. In contrast, very limited, if any, pharmaceutical approaches are
effective at increasing the Treg populations.
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cells (e.g., cancer) or infective agents (e.g., viruses and bacteria). This immuno-
suppressive state is most commonly exemplified by the progression and metastases
of cancers arising from a poor or impaired cellular immune response to abnormal
cells. Indeed, cancer progression is most often characterized by an impaired Teff
response; either due to failure in recognizing abnormal cells (i.e., ‘non-self’) or via an
existing immunosuppressive state arising from pharmacological agents or an inher-
ent skewing of the Treg:Teff response towards the Treg cells. Unlike immunosup-
pressive diseases, the focus of clinical therapy has historically focused on cytotoxic
chemicals that exert an enhanced lethality to cancer cells; though it is crucial to note
that these agents also exhibit toxicity to normal cells, especially populations char-
acterized by high proliferation rates (e.g., bone marrow; intestinal epithelial cells).
Only more recently has cancer therapy began to focus on immunomodulation; in
essence actively modulating the Treg:Teff ratio. Cancer immunotherapy has most
commonly utilized cytokine therapy or direct activation of T cells via mitogens or
monoclonal antibody therapy (Figure 3). However, both of these approaches are
beset by systemic toxicity limiting their practical use. More recently, adoptive
cellular therapeutic (ACT) approaches, using either allogenic T cells and/or CAR-T
cells, have been used. However, while clearly an increasingly important cancer
immunotherapy, these cellular approaches are expensive and, to date, continue to
pose a risk of uncontrolled immune activation and bystander cell injury [4–6].
4. Biological modulation of the immune response
While pharmacologic agents remain the mainstay of modern medicine in
treating both autoimmune diseases and cancers, a more direct ability to biologically
modulate the Treg:Teff ratio could, potentially, be a safer and more effective tool in
Figure 3.
Pharmacologic immunoactivation approaches have proven problematic due to their induction of poorly
controlled inflammatory responses. A common cause of toxicity to these approaches has been the induction of the
cytokine release syndrome (i.e., cytokine storm) [4–6].
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treating disease. It is worth noting that the biological modulation of the immune
response is not a new concept. Indeed, the theory and practice of proinflammatory
(i.e., decreasing the Treg:Teff ratio) immunotherapy originated with William
Coley’s treatment in 1891 of cancer patients with bacteria (and other toxins) in
order to induce an immune response that would exert a bystander effect on the
tumor mass [7–10]. This pioneering clinical research has led to the recognition of
Coley as the “Father of Immunotherapy”. Indeed, Coley’s Toxins were a mainstay of
cancer therapy for much of the early twentieth century and were marketed up to
1962. However, these biologics were poorly defined, subject to diverse
manufacturing standards (or lack thereof), and highly variable in their efficacy. By
the mid twentieth century, criticisms from within the medical community led to
less usage of Coley’s Toxins as they were supplanted by the newer, and ‘safer’,
developments of radiation therapy and chemotherapy; ironically both of which are
now recognized to pose very significant short- and long-term risks to the patient.
Indeed, it is these risks that are today driving forces in rediscovering
immunotherapy.
Today, 130 years after Coley’s Toxins made their initial debut, modern immu-
notherapy has begun to revisit Coley’s core principles of modulating (i.e., induc-
ing) the endogenous immune response. Several approaches have been pursued to
enhance the patient’s own immune response. Ironically, similarly to Coley’s use of
Streptococcus pyogenes and Serratia marcescens, genetically modified strains of
Salmonella sp. as well as recombinant polioviruses have been used in tumor ther-
apy to induce an inflammatory microenvironment at the tumor site [11–14].
Tumor-specific immunotherapy has also been explored in which cancer cells from
patients have been isolated, irradiated and modified for the re-infusion into the
patient in an attempt to enhance anti-tumor immune activation and improve
tumor killing [15–19]. But perhaps the favored approach has been the application
of adoptive cell transfer (ACT) immunotherapy and, especially, chimeric antigen
receptor (CAR)-T cell therapy [20–22]. While CAR-T cells will prove to be a
crucial tool in cancer immunotherapy, they are beset by significant issues includ-
ing cost, manufacturing time (weeks-months) and the risk of inducing cytokine
release syndrome [4–6].
However, of significant clinical importance, few studies/approaches to date have
elucidated effective biological immunotherapeutic approaches for modulating the
Treg:Teff ratio (Figures 2 and 3). The ability to biologically manipulate the Treg:
Teff ratio in a controllable manner would be of significant benefit in the treatment
of cancer as well as the treatment of autoimmune diseases and the prevention of
graft rejection.
5. A new approach to the biomodulation of the Treg:Teff ratio
As described in the preceding sections, pharmacologic agents, the current main-
stay of clinical medicine, are, relatively speaking, non-specific agents beset with
often significant adverse side effects. Hence, over the last decade increasing
research has been done on biologically modifying the innate Treg:Teff immune
response. In this chapter we will discuss a novel biomodulatory approach that more
effectively, and directly, target the Treg:Teff ratio by increasing or decreasing Treg
cells while simultaneously, and inversely, decreasing of increasing Teff subsets
(Figure 4). This approach, derived from our work on the polymer-based bioengi-
neering of allogeneic T cells and their use directly, or via the production of acellular
microRNA (miRNA), to induce a tolerogenic or proinflammatory state character-
ized by significant changes in the Treg:Teff ratio [23–35].
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Biomanufacturing of these immunomodulatory therapeutics was accomplished
using a rapid and inexpensive leukocyte allorecognition-based system (Figure 4)
[34, 35]. The core component of the biomanufacturing system is, in essence, a two-
way mixed lymphocyte reaction (MLR) in which MHC-disparate leukocyte
populations (either human PBMC or murine splenocytes) are co-incubated. Previ-
ous work from our laboratory demonstrated that the covalent grafting (PEGylation)
of methoxy(polyethylene glycol) [mPEG] to one leukocyte population resulted in
abrogation of the MHC-mediated proliferation of Teff cells [23–42]. Moreover,
these studies demonstrated that, consequent to impaired cell:cell communication
(Figure 4C), the weak allostimulation induced a tolerogenic/anergic state both
in vitro and in vivo (Figure 4A) [29–34, 41]. The PEGylated cells themselves, or the
resultant purified Treg cells, can be adoptively transferred to induce systemic tol-
erance in the recipient. Importantly, our studies demonstrated that the secretome of
PEGylated-MLR also exerted a tolerogenic effect in vitro and in vivo [25–27, 29–34].
In parallel to the PEGylated cells, the control MLR (Figure 4B) was used to
Figure 4.
Biomanufacturing immunomodulatory secretomes and purified miRNA. Panel A: Immunocamouflage of donor
cells by the covalent grafting of methoxy(polyethylene) glycol (mPEG) to one donor population in a mixed
lymphocyte reaction (MLR) results in the disruption of the essential cell–cell interactions (blue test) decreasing
T cell proliferation and altered subset differentiation patterns. As shown,Treg cells are vastly increased while
Teff subsets (CTL,Th1 and Th17 shown) are decreased resulting in an increase in the Treg:Teff ratio.
Importantly, the secretome from the mPEG-MLR exerts a tolerogenic response when used either in vitro or
in vivo. The key component of the secretome are miRNA. Panel B: Current pharmacologic therapy almost
exclusively targets T cell activation and proliferation consequent to allorecognition. Response to non-self is in
large part mediated by cell–cell interactions between antigen presenting cells (APC; e.g., dendritic cells) and
naive T cells. This cell–cell interaction is characterized by essential adhesion, allorecognition and co-stimulation
events. Consequent to allorecognition, a proliferation of proinflammatory T cells (e.g., cytotoxic T lymphocyte,
CTL; Th17, IL-17+; Th1, IFN-γ+; and IL-2+ populations) and decrease in regulatory T cells (Treg, Foxp3+
and CD25+) is observed. Panel C: As shown in photomicrographs, in a control MLR, significant and persistent
interactions (black arrows) occur between allogeneic lymphocytes (LYM) and dendritic cells (APC). The
lymphocyte adhesion and antigen presentation interactions typically occur at pseudopodal extensions from the
APC (white arrows). PEGylation of either allogeneic PBMC population decreases the stability and duration of
initial cell:cell interactions between lymphocytes due to the global charge and steric camouflage of membrane
proteins. Panel D: Importantly, the secretomes/miRNA bioproduction is both simple and rapid. As shown,
allogeneic leukocytes (a, b) are incubated for 5 days and the secretome is collected. The secretome itself can be
used or the miRNA component of the secretome can be further isolated for use. Both the secretome and miRNA
can be stored frozen as they are stable under freeze–thaw conditions. The key component of the secretome are
soluble (free and exosome) miRNA. Size of the T cell populations denotes increase or decrease in number.
Apoptosis is indicated by blebbing. Data derived from Refs. [23–35]. Figure modified from Scott et al. [35].
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generate a proinflammatory secretome, or with further purification, miRNA prep-
aration that could induce a controlled inflammatory response in unactivated T cells
[25–27, 29–34]. Most importantly, the process is rapid (5 days), inexpensive and can
be accomplished using stand tissue culture facilities—though also suitable for larger
scale bioreactor systems (Figure 4D).
The two biomanufactured miRNA-enrich therapeutics, denoted as TA1 for the
tolerogenic preparation and IA1 for the proinflammatory preparation, exert potent
immunomodulatory effects on T cells differentiation (Figure 5). TA1 drives the
differentiation of CD3+CD4CD8 T cells towards Treg cells (CD4+Foxp3+CD25+)
while IA1 drives T cell proliferation towards both CD4+ Th17 and Th1 cells and also
towards CD3+CD8+ cytotoxic T lymphocytes (CTL). Thus, stable and storable
(freeze–thaw stable) tolerogenic and proinflammatory biologics can be rapidly
(5 days) and reproducibly biomanufactured.
Importantly, the active component of the TA1 and IA1 therapeutics are miRNAs—
not cytokines or other potential immunomodulatory effectors [31, 34, 35]. The role
of miRNA can be seen by the loss of immunomodulatory activity of TA1 and IA1
conditioned murine plasma upon treatment with RNase (Figure 6). As shown,
naïve control mice (N) have high levels of Treg cells relative to Th17 cell. However,
when challenged with a transfusion of allogeneic cells (AC), by day 5 Treg cells
have decreased significantly with a concomitant increase in Th17. However, if naïve
mice are pretreated with TA1 or IA1, the immune response to the allogeneic cells is
dramatically altered. TA1 pre-treatment resulted in a maintenance, and slight ele-
vation, of normal murine Treg levels and prevention of the Th17 upregulation upon
allogeneic challenge. In contrast, IA1 pre-treatment enhanced the inflammatory
response to the allogenic cells; i.e., significantly decreased Treg and increased Th17
cells relative to both naïve mice and control AC challenged mice. Importantly,
RNase treatment of the TA1 or IA1 samples to degrade the miRNA component
resulted in the attenuation of their respective immunomodulatory activity resulting
in a T cell response virtually identical to the AC treated control mice.
Figure 5.
In vitro and in vivo flow cytometric and functional analyses of T cells demonstrates that the TA1 and IA1
therapeutics differentially skew the differentiation pattern of naive CD3+CD4CD8 T cells. As shown
diagrammatically,TA1 favors tolerogenic/anergic T cell subsets while significantly inhibiting proinflammatory
Teff populations. Conversely, as shown by the skewing of the Treg:Teff ratio, IA1 induces differentiation and
proliferation of both CD4+ and CD8+ Teff subsets while reducing Treg populations.
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6. Treatment of autoimmune diseases via Treg:Teff modulation
Autoimmunity arises consequent to an animal/individual’s immune system rec-
ognizing their own tissues as ‘non-self’. The Non-Obese Diabetic (NOD) mouse is an
inbred strain that exhibits the spontaneous development of a variety of autoim-
mune diseases including insulin dependent T1D. The murine autoimmune diabetes
develops spontaneously around 16–20 weeks of age though studies indicate that the
autoimmune process begins by weeks 3–4 [43–51]. Of note, the NOD mouse has
been extensively used to study the mechanisms underlying autoimmune-mediated
diabetes as well as to evaluate therapeutic interventions on disease pathogenesis. To
investigate the ability of TA1 to attenuate disease progression and incidence,
7-week-old NOD mice were treated with TA1—no other interventions were done.
As demonstrated in Figure 7A, the onset and incidence of diabetes was assessed
and correlated with the Treg:Teff ratio of the mice [31–35]. As shown, 75% of the
untreated NOD mice, but only 40% of the TA1 treated mice, developed T1D. The
onset of T1D was correlated with the Treg:Teff ratios of the individual mouse
(Panel A). As shown, the TA1 treated mice exhibited significantly increased Treg:
Teff ratio which correlated with significantly delayed onset of the disease in the
mice that became diabetic. Mice with very high Treg:Teff ratios (average > 250) in
either the control or TA1 treated mice remained normoglycemic. Moreover, TA-
treatment was associated with improved islet histology (Figure 7B) as reflected by
the lower incidence of overt insulitis and peri-insulitis. Indeed, no normal islets
were observed in the control diabetic NOD mice. In contrast, in TA1 treated mice
that became diabetic, almost 20% of their islets exhibited normal morphology—
more than that observed in normoglycemic NOD mice at 30 weeks. In the
normoglycemic TA1 treated mice > 40% of the islets exhibited normal histology.
Mechanistically, the changes noted in the Treg:Teff ratio (using Foxp3+ and
Th17+ lymphocytes as surrogates for Treg and Teff, respectively) correlating with
the changes noted in multiple T cell subsets [31]. As shown in Figure 8, analysis of
the pancreatic lymph node demonstrated that TA1 induced multiple tolerogenic T
cell subpopulations (e.g., Foxp3+, IL-10+, TGF-β+ and IL-4+ CD4+ T cells) and down
regulated multiple Teff subgroups (Th17+, IL-2+, INF-γ+ and TNF-β+ CD4+ cells).
Figure 6.
The active component of TA1 and IA1 are miRNA as evidenced loss of immunomodulatory activity consequent
to RNase treatment. A microRNA (miRNA) specific preparation made from mice previously treated (5 days
prior) with mPEG-allogeneic leukocytes yielded a systemic immunomodulation (increased Tregs, decreased
Th17 T cells) very similar to the mPEG-cellular product within the spleen of mice 5 days post treatment with
the miRNA preparation. As shown, the immunomodulatory effect is lost by treatment with RNase enzymes.
N = naïve mice; AC = allogeneic cells; miRNA alloplasma fraction  RNase; and mPEG-alloplasma  RNase.
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Hence, TA1 effectively skewed the Treg:Teff ratio towards a tolerogenic-
immunosuppressive environment within the pancreas that consequently inhibited
the effector T cell dependent autoimmune disease process. Importantly, the TA1
induced immunomodulation was not limited to the pancreas as T cell subtyping of
multiple lymphoid tissues, as well and the blood, demonstrated that the induced
tolerogenic environment was systemic in nature [31]. These systemic findings
Figure 7.
Inhibition of T1D in the NOD mouse via induction of immunosuppression by the administration of
immunomodulatory miRNA. Panel A: Age of onset for T1D versus the Treg:Teff ratio in the control and TA1-
treated NOD mouse. Note that TA1 therapy dramatically increased the Treg:Teff ratio and delayed both onset
and incidence of T1D. In contrast, in control NOD mice the Treg:Teff ratio shifted left towards the expansion of
Teff cells and disease progression. Panel B: Shown are the percentages of pancreatic islets exhibiting normal
morphology or evidence of insulitis or peri-insulitis. Also shown are photomicrographs of islets exhibiting (left to
right) normal morphology, peri-insulitis and insulitis. Data from Wang et al. [31].
Figure 8.
Effect of TA1 therapy on T CD4+ T cell populations. As shown,TA1 therapy significantly increased multiple
Treg populations in comparison to the control NOD mice. Concurrent with the increase in Treg subsets,TA1
very dramatically reduced the Teff subpopulations. The net consequence of TA1 therapy was a significant shift
in the Treg:Teff ratio towards a tolerogenic state. Data from Wang et al. [31].
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suggest that TA1 could be used to treat a broad range of T cell mediated
autoimmune diseases.
7. Enhancing the anti-cancer response via Treg:Teff modulation
In contrast to autoimmune diseases, systemic immunosuppressive states can
be highly problematic in the context of infectious agents (e.g., bacteria and
viruses) and cancer. Indeed, this lack of immune response to cancer was the
problem that Coley attempted to address with his immunomodulatory prepara-
tions. By injecting a toxic mixture, a broad immune response would be induced
that, it was HOPED, would exert a non-specific bystander effect on cancer cells.
This was, in fact, a relatively viable clinical approach as cancer cells tend to be
more sensitive to metabolic (e.g., high fever, energy starvation) and immuno-
logical (e.g., T cell and complement activation) extremes. Indeed, Coley’s Toxins
were a mainstay of advanced cancer therapy for much of the early/mid twentieth
century until their use was supplanted by ‘safer’ radiation and chemo- therapy
approaches. But ‘safe’ is not always ‘safe’. The long-term toxicity effects of both
radiation and chemotherapy are now becoming appreciated—especially when
used in young patients. Hence, significant clinical efforts are now being directed
towards increasingly expensive and labor/time intensive, immunotherapies that
can either enhance the endogenous immune response to cancers or be engineered
to attack specific cancers.
In contrast to these expensive and time-extensive cellular therapies, the
bioproduction of IA1(as well as TA1) is rapid and inexpensive. Moreover, minimal
time (24 hours) is required to skew the Treg:Teff ratio of resting PBMC towards an
inflammatory response arising from the simultaneous decrease of Treg and increase
in Teff [34]. Hence IA1 could be used to enhance the immune response of autolo-
gous leukocytes thus obviating the risks associated with the adoptive transfer of
allogenic T cells. Moreover, the strength of the inflammatory response is substan-
tially less than that observed with other activation strategies (e.g., mitogens, anti-
CD3, of allogeneic stimulation) reducing the risk of cytokine release syndrome [34].
Also, of potential value, the strength of the IA1 stimulation can, if necessary, be
titrated using TA1.
To evaluate the potential anti-cancer efficacy of IA1 activated leukocytes,
in vitro studies were conducted using HeLa and SH-4 melanoma cell lines
(Figure 9) [34]. The direct toxicity and anti-proliferative effects of control and the
SYN (prepared from resting cells) or IA1 treated PBMC against the HeLa (epithe-
lial) and SH-4 (melanoma) human cancer cell lines were assessed using an ACEA
iCELLigence (ACEA Biosciences, Inc., San Diego, CA). The iCELLigence provides a
continuous, real-time, measurement of cell proliferation using changes in the elec-
trical impedance within tissue culture wells. The change in impedance is induced by
the increase in adherent cells and is unaffected by cells (e.g., PBMC) that remain
non-adherent. All studies were done with an initial seeding density of 5000 HeLa,
or 20,000 SH-4, cells per well. To assess the ability of SYN- or IA1-activation to
enhance the anti-cancer efficacy of naïve lymphocytes, donor PBMC were
pretreated with SYN or IA1 for 24 hours and then overlaid on seeded cancer cells at
a ratio of 50 PBMC per cancer cell.
As shown, direct addition of IA1 to HeLa cells demonstrated that the IA1 thera-
peutic itself exhibited no direct effects on cancer cell proliferation (Figure 9A).
However, when HeLa cells were overlaid with unactivated or SYN-activated allo-
genic donor PBMC, the T cells eventually recognized the allogenic HeLa cells and,
after 90 hours, inhibited cell proliferation and, ultimately, killed the HeLa cells as
10
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reflected by the decrease in the impedance index. In contrast, when IA1-activated
PBMC were overlaid, the inhibition of HeLa cell proliferation was noted within the
first 8–12 hours (versus 90 hours) dramatically reducing the overall proliferation
of the HeLa cells (Figure 9B). The anti-cancer efficacy of IA-activated PBMC was
not limited to HeLa cells. Further studies using SH-4 melanoma cells also demon-
strated that IA1-activation of naïve PBMC induced a potent anti-cancer effect
(Figure 9C). As noted, control SH-4 melanoma cells showed rapid proliferation
over 96 hours. However, when untreated SYN-pretreated PBMC (50 PBMC per SH-
4 cell) were overlaid onto the seeded SH-4 cells at 0 hours, a significant, but
modest, inhibition of SH-4 growth occurred. However, when IA1-pretreated
(24 hours) PBMC from the same donor are overlaid on the SH-4 cells, a greatly
enhanced anti-cancer effect was noted relative to untreated PBMC. The enhanced
efficacy of treated PBMC was supported by photomicrographs of allogenic PBMC
responding to HeLa cells (Figure 9D). As shown, after 72 hours incubation, SYN-
activated PBMC exhibited limited interaction with the HeLa cells. In contrast, the
same PBMC, when pre-treated for 24 hours with IA1, demonstrated a significantly
enhanced interaction with the HeLa cell monolayer. Hence, in vitro, IA1 is capable
of significantly enhancing the anti-cancer efficacy of resting PBMC. As such the
secretome generated IA1 proved to be a potent adjuvant therapy for the activation
of autologous lymphocytes in cancer patients. This approach could be done either
by collection of PBMC with ex vivo activation for 24 hours, or as shown in
Figures 6–8, direct systemic administration of the IA1-therapeutic to the patient.
Moreover, this methodology could be used in conjunction with other ACT
approaches.
Figure 9.
IA1 enhances the anti-cancer efficacy of resting PBMC. Panel A: IA1 exhibits no direct toxicity to HeLa cells
(shown) or PBMC (not shown). Panel B: IA-1 pre-treatment, but not SYN-pre-treatment, exhibited a greatly
enhanced anti-cancer effect on HeLa cells. Panel C: Similarly to HeLa cells, IA1, but not SYN, pre-treated
PBMC exhibited significant anti-SH-4 (melanoma) activity. Panel D: The enhanced efficacy of treated PBMC
is supported by photomicrographs of allogenic PBMC responding to HeLa cells. As shown, after 72 hours
incubation, resting unactivated PBMC show limited interaction when overlaid on HeLa cells. In contrast, the
same PBMC, when treated for 24 hours with IA1, show a robust enhanced interaction with the HeLa cell
monolayer. Cell proliferation was measured by changes in electrical impedance. SYN (derived from the
secretome of resting PBMC) or IA1-pretreated utilized PBMC from the same donor. Modified from Yang et al.
[34] and Scott et al. [35].
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8. Regulating the Treg:Teff ratio: toxicity and ping-pong immunology
Importantly, treatment of mice or cells with mPEG-splenocytes or the TA1 and
IA1 (see Figure 9A) secretome products exerted no evidence of direct acute toxicity
[27, 31, 34, 35]. Indeed, the safety of allogenic mPEG-splenocytes was demonstrated
in a murine model of transfusion associated graft versus host disease in which it was
shown that transfusion of mPEG-splenocytes were incapable of inducing graft
versus host disease in immunocompromise (irradiated) mice [25]. This is not to say
that these approaches may not be prone to chronic side effects. Immunosuppressive
therapy, i.e., tolerization, is known to increase the risk of cancer. Thus, the long-
term persistence of the effects of mPEG-leukocytes or TA1 [35] could pose a similar
risk. Indeed, our previous studies have demonstrated that the immunomodulatory
effects of both the PEGylated allogenic splenocytes and the TA1 and IA1 secretome
products extend well beyond the circulation time of donor lymphocytes and exhibit
functional activity both in vitro and in vivo [27, 31, 33–35]. For example, in mice
treated with allogenic mPEG-splenocytes, the Tregs remained significantly elevated
at 30 days post treatment and, when challenged with a secondary transfusion of
unmodified allogenic splenocytes, prevented the expected (decreased Treg and
increased Teff) proinflammatory effects of the allogenic splenocyte transfusion.
Figure 10.
Ping-pong immunology of TA1 and IA1. Panel A: Shown are the Treg (Foxp3+) and Teff (Th17) CD4+ cells in
the spleen of mice treated with a primary (1°) infusion of either TA1 or IA1. A subset of mice were subsequently
received a secondary (2°) infusion with the opposing therapeutic (IA1 or TA1) at day 9. Lymphoid organs
(spleen shown) were harvested at day 40. As noted by the absolute percentage of CD4+ T cells and the delta (△)
d/d’ from naïve mice, primary (1°) treatment with TA1 and IA1 alone gave the expected Treg and Teff
response. The 2° treatment with the opposite miRNA preparation was able to significantly counterbalance the
effect of the 1° treatment. This is reflected by the △d2 and △d2’ bars and the regression of the Treg and Th17
values towards the mean of naïve mice. As expected based on the magnitude of the 1° treatment, the △d2 and △d2’
bars were greater than the initial △d/d’ values. This is most obvious with the Th17 cells where both the
magnitude and actual decrease in the 2° △d2 (1.5%) for TA1 was significantly greater than 1° △d (0.15%).
Panel B: PD-1+ (CD279+) CD4+ T cells are important in downregulating the immune response and promoting
self-tolerance via suppression of Teff cell populations. As shown, transfusion of allogeneic splenocytes
downregulated, while mPEG-allogenic splenocytes upregulated, PD-1+ cells relative to naïve, saline treated,
mice. Shown are the PD-1+ cells in the spleen of mice treated with a primary (1°) infusion of either allogenic or
mPEG-allogenic at day 0 (denoted as 1) or a total of 3 injections given at days 0, 2 and 4 (denoted as 3).
Spleens were harvested at either day 5 or 10 for determination of T cell subpopulations. N ≥ 5 for all samples
shown. Significance: * p < 0.01 from naïve mice; # p < 0.01 from primary TA1 or IA1 (panel a) or; panel B
from 1 or 3 doses.
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Indeed, the Treg remained high and no Th17 cells were induced [27]. Long-term
studies of mice treated once with TA1 also demonstrated a persistent, and signifi-
cant, elevation in their Treg cells for ≥270 days [35]. Hence, the potent immuno-
modulatory effects of this approach could be of concern.
As noted above, the persistence of the Treg response, even upon allogenic
challenge, while beneficial in the treatment of autoimmune diseases could pose
immunological risks. However, TA1 and IA1 target the same miRNA-based
bioregulatory pathway governing lymphocyte differentiation and proliferation.
Because of this, TA1 and IA1 are capable of counter-acting the activity of the other.
This ‘ping-pong immunology’ in mice is demonstrated in Figure 10A. As noted,
treatment with TA1 or IA1 inversely affects the Treg and Teff populations (Δd,
Δd’). However, subsequent administration of the IA1 to TA1 treated mice, or vise-
versa, resulted in the Treg and Teff cell populations reverting towards the homeo-
static level noted in naïve, untreated, mice (Δd2, Δd2’). The immunomodulatory
‘ping-pong’ activity of TA1 and IA1 can be further fine-tuned via dosing, as both TA1
and IA1 show dose dependent activity [31–35]. Also of note, the immunomodula-
tory activity of this technology is correlated with other markers of tolerance or
inflammation. Transfusion of mPEG-splenocytes triggers a significant upregulation
of PD-1+ (CD279) CD4+ lymphocytes (Figure 10B). These PD-1+ cells are impor-
tant in downregulating the immune response and promoting self-tolerance via
suppression of Teff cell populations. The expression of PD-1+ T cells may underlie
the production of IL-10+ T cells as noted in Figure 8. In contrast to TA1 treatment,
both unmodified allogenic cells (shown) and IA1 treatment (not shown) decrease
PD-1 expression relative to naïve mice. A dose effect on PD-1 expression can be
seen with both allogenic and, especially, mPEG-allogenic cells in mice receiving 1 or
3 injections (at days 0, 2 and 4) of cells when assessed at days 5 and 10 post
treatment.
9. Conclusions
Immunosuppression and immunoactivation represent the divergent ends of
the Treg:Teff ratio continuum (Figure 1). While pharmacologic agents have
historically been the primary tools for modulating the Teff response, few
options have existed for modulating (especially upregulating) the Treg
response. However, the direct immunomodulation of the endogenous immune
system may have significant clinical benefit in treating a broad range of clinical
conditions ranging from autoimmune diseases, tissue/organ engraftment, and
cancer. Extensive in vitro and in vivo studies in our laboratory have demon-
strated that PEGylated lymphocytes as well as the biomanufactured TA1 and
IA1 exhibited significant immunomodulatory activity [23–42, 52]. Indeed, these
agents directly altered the Treg:Teff ratio by simultaneously modulating both
regulatory and effector T cell subsets. Consequent to their immunomodulatory
activity, the immunosuppressive TA1 therapeutic significantly delayed the
onset and overall incidence of autoimmune diabetes in the NOD mouse [31].
Conversely, the proinflammatory IA1 therapeutic directly activated T cells
overcoming their inherent immunological inertia resulting in enhanced recog-
nition and killing of cancer cells [34]. The immunomodulatory effects of these
agents were highly persistent [35]. The TA1 and IA1 agents showed dose
dependency and could be used to counteract the effect of on another [31–35].
The successful development of these immunomodulatory therapeutics may
prove useful in facilitating organ engraftment, treating autoimmune disease and
enhancing the endogenous anti-cancer response.
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